vs
Side-by-side financial comparison of AGENUS INC (AGEN) and AIM ImmunoTech Inc. (AIM). Click either name above to swap in a different company.
AGENUS INC is the larger business by last-quarter revenue ($34.2M vs $21.0K, roughly 1628.8× AIM ImmunoTech Inc.). AGENUS INC runs the higher net margin — -31.0% vs -19881.0%, a 19849.9% gap on every dollar of revenue. On growth, AGENUS INC posted the faster year-over-year revenue change (27.5% vs -53.3%). Over the past eight quarters, AGENUS INC's revenue compounded faster (10.5% CAGR vs -27.5%).
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
AGEN vs AIM — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $34.2M | $21.0K |
| Net Profit | $-10.6M | $-4.2M |
| Gross Margin | — | — |
| Operating Margin | 42.1% | -14057.1% |
| Net Margin | -31.0% | -19881.0% |
| Revenue YoY | 27.5% | -53.3% |
| Net Profit YoY | 77.3% | 30.0% |
| EPS (diluted) | $0.09 | $-6.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.2M | $21.0K | ||
| Q3 25 | $30.2M | $26.0K | ||
| Q2 25 | $25.7M | $25.0K | ||
| Q1 25 | $24.1M | $16.0K | ||
| Q4 24 | $26.8M | $45.0K | ||
| Q3 24 | $25.1M | $35.0K | ||
| Q2 24 | $23.5M | $50.0K | ||
| Q1 24 | $28.0M | $40.0K |
| Q4 25 | $-10.6M | $-4.2M | ||
| Q3 25 | $63.9M | $-3.3M | ||
| Q2 25 | $-30.0M | $-2.8M | ||
| Q1 25 | $-26.4M | $-3.7M | ||
| Q4 24 | $-46.8M | $-6.0M | ||
| Q3 24 | $-67.2M | $-3.7M | ||
| Q2 24 | $-54.8M | $-1.8M | ||
| Q1 24 | $-63.5M | $-5.8M |
| Q4 25 | — | — | ||
| Q3 25 | 97.9% | — | ||
| Q2 25 | 99.1% | — | ||
| Q1 25 | 99.4% | — | ||
| Q4 24 | 99.6% | — | ||
| Q3 24 | 99.4% | — | ||
| Q2 24 | 99.5% | — | ||
| Q1 24 | 99.6% | — |
| Q4 25 | 42.1% | -14057.1% | ||
| Q3 25 | -15.0% | -9411.5% | ||
| Q2 25 | -65.0% | -10584.0% | ||
| Q1 25 | -55.3% | -22618.8% | ||
| Q4 24 | -96.5% | -13011.1% | ||
| Q3 24 | -125.5% | -12825.7% | ||
| Q2 24 | -128.4% | -7388.0% | ||
| Q1 24 | -117.4% | -14335.0% |
| Q4 25 | -31.0% | -19881.0% | ||
| Q3 25 | 211.4% | -12630.8% | ||
| Q2 25 | -116.8% | -11176.0% | ||
| Q1 25 | -109.6% | -23156.3% | ||
| Q4 24 | -174.4% | -13260.0% | ||
| Q3 24 | -267.7% | -10571.4% | ||
| Q2 24 | -233.1% | -3672.0% | ||
| Q1 24 | -226.6% | -14542.5% |
| Q4 25 | $0.09 | $-6.46 | ||
| Q3 25 | $1.94 | $1.57 | ||
| Q2 25 | $-1.00 | $-3.68 | ||
| Q1 25 | $-1.03 | $-0.05 | ||
| Q4 24 | $-1.95 | $-21.80 | ||
| Q3 24 | $-3.08 | $-6.00 | ||
| Q2 24 | $-2.52 | $-3.00 | ||
| Q1 24 | $-3.04 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $3.0M |
| Total DebtLower is stronger | $44.7M | $4.5M |
| Stockholders' EquityBook value | $-271.1M | $-9.8M |
| Total Assets | $226.8M | $5.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $3.0M | ||
| Q3 25 | $3.5M | $2.4M | ||
| Q2 25 | $9.5M | $835.0K | ||
| Q1 25 | $18.5M | $2.2M | ||
| Q4 24 | $40.4M | $4.0M | ||
| Q3 24 | $44.8M | $7.2M | ||
| Q2 24 | $93.7M | $10.1M | ||
| Q1 24 | $52.9M | $10.9M |
| Q4 25 | $44.7M | $4.5M | ||
| Q3 25 | $34.2M | — | ||
| Q2 25 | $33.9M | $2.7M | ||
| Q1 25 | $33.6M | $2.4M | ||
| Q4 24 | $33.2M | $2.8M | ||
| Q3 24 | — | $3.3M | ||
| Q2 24 | — | $3.3M | ||
| Q1 24 | — | $3.3M |
| Q4 25 | $-271.1M | $-9.8M | ||
| Q3 25 | $-274.1M | $-6.1M | ||
| Q2 25 | $-354.6M | $-6.5M | ||
| Q1 25 | $-341.8M | $-3.9M | ||
| Q4 24 | $-326.4M | $-1.3M | ||
| Q3 24 | $-292.3M | $2.9M | ||
| Q2 24 | $-241.3M | $6.1M | ||
| Q1 24 | $-201.4M | $4.8M |
| Q4 25 | $226.8M | $5.8M | ||
| Q3 25 | $233.9M | $5.5M | ||
| Q2 25 | $185.2M | $4.1M | ||
| Q1 25 | $200.2M | $6.2M | ||
| Q4 24 | $226.3M | $8.6M | ||
| Q3 24 | $238.5M | $13.6M | ||
| Q2 24 | $292.4M | $15.7M | ||
| Q1 24 | $256.6M | $16.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.13× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 0.69× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.6M | $-2.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.6M | $-2.0M | ||
| Q3 25 | $-14.7M | $-5.1M | ||
| Q2 25 | $-20.2M | $-1.5M | ||
| Q1 25 | $-25.6M | $-2.4M | ||
| Q4 24 | $-28.7M | $-4.0M | ||
| Q3 24 | $-53.3M | $-3.1M | ||
| Q2 24 | $-38.2M | $-3.0M | ||
| Q1 24 | $-38.2M | $-4.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-20.2M | — | ||
| Q1 25 | $-25.6M | — | ||
| Q4 24 | $-28.7M | — | ||
| Q3 24 | $-53.3M | — | ||
| Q2 24 | $-38.6M | — | ||
| Q1 24 | $-38.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -78.7% | — | ||
| Q1 25 | -106.5% | — | ||
| Q4 24 | -107.0% | — | ||
| Q3 24 | -212.2% | — | ||
| Q2 24 | -164.4% | — | ||
| Q1 24 | -136.5% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.23× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
